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Background: The negative influence of cardiopulmonary bypass on hemo- 
stasis has been documented. Although abnormalities in platelet function 
are reported as the major cause of postoperative blood loss related to this 
hemostasis defect, fresh frozen plasma is often used in operations with 
cardiopulmonary bypass because it is thought to contribute to the reduction 
of postoperative bleeding complications. This study was designed to eval- 
uate the effect of the administration of fresh frozen plasma after cardio- 
pulmonary bypass on blood loss, transfusion requirements, and a number 
of coagulation parameters. Methods: In a prospective, randomized, double- 
blind clinical trial 50 patients (mean age 63 years; 35 men/15 women) 
undergoing elective operation with cardiopulmonary bypass were randomly 
assigned to one of two groups: group I (n = 24) received 3 units of fresh 
frozen plasma after operation and group II (n = 26) received an equal 
amount of Gelofusine plasma substitute. At seven points before, during, 
and after operation hemoglobin concentration, hematocrit level, thrombo- 
cyte count, and coagulation parameters were analyzed. Study endpoints 
were the volume of blood loss and the transfusion requirement. Results: 
There were no significant differences between the two study groups in blood 
loss, transfusion requirement, coagulation parameters, or thrombocyte 
counts. Conclusion: The routine use of fresh frozen plasma in operations 
with cardiopulmonary bypass cannot be recommended. (J Thorac Cardio- 
vasc Surg 1996;112:162-7) 
T he influence of cardiopulmonary b pass (CPB) on hemostasis has been the subject of many 
studies. ~-6 These studies revealed that bnormalities 
in platelet function are probably the major cause of 
postoperative loss of blood in operations with 
CPB.7, a There are data that suggest hat an in vivo 
lack of platelet agonists (for example, thrombin, 
which is inhibited by heparin) plays an important 
role in the observed defect in platelet function? 
Although clotting factors decrease during CPB, the 
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levels are still adequate for normal coagulation. 1' 7 
Although the only indication for the use of fresh 
frozen plasma (FFP) is bleeding caused by proven 
coagulation abnormalities, FFP is often used in 
patients undergoing cardiac operation, because it is 
thought o reduce postoperative bleeding complica- 
tions.l-4, 9
In view of the risks of transfusion of blood 
products, for example, the transmission of viral 
infections, the induction of immunologic transfu- 
sion reactions, and the negative influence on the 
immune system, unnecessary transfusions should be 
avoided. 10-15 The aim of the current study was to 
investigate whether the prophylactic use of FFP in 
the immediate postoperative phase in patients un- 
dergoing cardiac operation decreases blood loss and 
transfusion requirement. 
Patients and methods 
In a prospective, randomized, double-blind study we 
compared the effects of FFP and of Gelofusine plasma 
substitute (Vifor Medical SA, Switzerland) on blood loss 
and transfusion requirement in 50 patients undergoing 
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operation with CPB. After the end of the operation the 50 
patients (mean age 63 years; 35 men/15 women) were 
randomly assigned to one of two groups: group I (n : 24) 
received 3units of FFP and group II (n = 26) received 750 
ml of a modified gelatin solution (Gelofusine plasma 
substitute). All patients underwent coronary artery bypass 
grafting as the operative procedure. Because we wanted to 
exclude as many variables as possible no patients under- 
going valve replacement were included. 
Exclusion criteria were a preexisting coagulopathy (ab- 
normal values in preoperative activated partial thrombo- 
plastin time [aPTT], prothrombin time [PT], or platelet 
count, or platelet dysfunction known from history), a left 
ventricular ejection fraction of less than 40%, reopera- 
tions (because of the usually extended extracorporeal 
circulation period), and an extracorporeal circulation time 
that exceeded 2 hours (because prolonged extracorporeal 
circulation time is known to increase hemostatic defects). 
Blinding was ensured by use of two independent inves- 
tigators, one in the operating room and one in the 
intensive care unit (ICU) and on the ward. The latter was 
unaware of whether FFP or Gelofusine plasma substitute 
had been administered. The randomization envelope was 
opened at the end of the surgical procedure. 
Informed consent was obtained from all 50 patients. 
The study was approved by the local Institutional Medical 
Ethical Committee. 
Anesthesia and CPB technique. All patients were pre- 
medicated according to a standard protocol. Anesthesia 
was accomplished by means of a standardized high-dose 
fentanyl regimen in combination with pancuronium bro- 
mide for muscle relaxation. Intermittent positive-pressure 
ventilation was used to maintain ormocapnia. 
Operation was done according to a standard technique 
with a midline sternotomy. The extracorporeal circuit 
contained a Cobe-CML membrane oxygenator (Cobe 
Laboratories, Lakewood, Colo.). Systemic mild hypother- 
mia (28 ° C) was maintained. A pump flow rate of 2.1 
L/min per square meter was used. The circuit was primed 
with 500 ml Ringer's lactate solution, 1500 ml polygeline, 
100 ml mannitol 20%, and 50 ml NaHCO 3 8.4%. An 
average of 1200 ml of cardioplegic solution (St. Thomas' 
Hospital No. 1) was used. Systemic anticoagulation was 
accomplished by intravenous administration of 300 units 
of heparin per kilogram body weight. After the patient 
had been weaned from bypass, the heparin was antago- 
nized with protamine sulfate in a ratio of 1.5 mg/125 U of 
the initial heparin dose. 
No FFP was given before or during operation. Between 
the end of operation and the patient's admission into the 
ICU, either 3 units of FFP or 750 ml of Gelofusine plasma 
substitute was administered. Homologous packed red 
blood cells were infused if the hematocrit level was less 
than 0.20 L/L after the bypass procedure or less than 0.25 
L/L in the ICU. No autotransfusion was done either 
before or after operation. 
Laboratory studies. Blood samples were taken at the 
following times: before induction of anesthesia, fter the 
administration of heparin, after protamine administra- 
tion, at the end of the operation, 2 hours after operation 
in the ICU, 6 hours after operation in the ICU, 24 hours 
after operation, and on the fifth postoperative day. The 
blood samples for measurement of hematologic parame- 
ters were drawn into 5 ml vacuum containers (Vacutainer, 
Becton Dickinson Division, Franklin Lakes, N.J.) contain- 
ing 0.04 ml of potassium ethylene diaminetetraacetic acid. 
Hemoglobin, hematocrit, platelet, and leukocyte counts 
were done on an H1 Technicon instrument (Technicon 
Instruments Corp., Tarrytown, N.Y.). An additional 5 ml 
of blood was drawn into 5 ml vacuum containers that 
contained 0.05 ml of sodium citrate for determination of
the following coagulation parameters: aPTT and PT, 
which were measured with a KC 10 (Amelung, Lengo, 
Germany), and fibrinogen, which was assayed on an MLA 
instrument (Medical Laboratory Automation Inc., New 
York, N.Y.). Intraoperatively, the activated clotting time 
was measured with the Hemochron i strument (Hemotec, 
International Technidyne Inc., Edison, N.J.), with use of 
kaolin-activated tubes. Fluid loss and fluid requirement 
were recorded until postoperative day 6; additionally, all 
medications and complications were recorded. 
Statistical analysis. Statistical analysis was done by the 
Mann-Whitney test for unpaired samples, after an analysis 
of variance. A p value <0.05 was considered to be 
statistically significant. 
Results 
Patient groups. The mean age and weight of 
patients in group I (n = 24, male/female ratio 20/4) 
were 62 years (range 46 to 75 years) and 81 kg 
(range 56 to 98 kg), respectively. In patients in group 
II (n = 26, male/female ratio 15/11) these values 
were 63 years (range 49 to 75 years) and 76 kg 
(range 54 to 83 kg), respectively. The only significant 
difference (p < 0.01) between groups was the male/ 
female ratio (group I: 5:1, group II: 3:2.2). 
Total blood loss in the entire study population 
ranged from 1625 ml to 1792 ml. There was no 
statistically significant difference between the two 
groups. On analysis of blood loss during two sepa- 
rate periods (operative period and ICU period), 
there were also no significant differences between 
groups (operative period: group I, 896 + 212 ml; 
group II, 849 +_ 172 ml, and ICU period: group I, 
896 _+ 104 ml; group II, 776 + 76 ml; Fig. 1). 
As might be expected from the blood loss data, 
there were no significant differences in the transfu- 
sion requirement of packed red blood cells between 
the groups at any time (operating room: group I, 
550 _+ 1077 ml; group II, 495 + 45 ml, ICU: group 
I, 608 +_ 152 ml; group II, 756 +_ 79 ml; Fig. 2). No 
patient in group I I  received FFP. Additional fluids 
infused are depicted in Fig. 2. During the entire 
study period there were no statistically significant 
differences in fluid balance between the two groups 
(Fig. 3). 
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Fig. 1. Blood loss in milliliters in group I (solid bars) and in group II (dotted bars). Values shown for blood 
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Fig. 2. Infusion regimen (means and standard error of mean i  milliliters) during operation (OR), in ICU, 
and on ward in group I (solid bars) and in group II (dotted bars). Gelo, Gelofusine plasma substitute; PC, 
packed red blood cells; Chr, crystalloids. 
Hematologic parameters. At all sample times 
minimal but significant differences between groups 
were found in hemoglobin and hematocrit levels. 
Preoperatively these latter parameters were already 
significantly higher in group I. This was probably a 
result of the difference in the male/female ratio 
(group I: 5:1 versus group II: 3:2.2). When statistical 
correction was done for this confounder, there were 
no significant differences between groups. The 
courses of the hemoglobin concentrations in both 
groups, subdivided into male and female popula- 
tions, are depicted in Fig. 4. 
Hemostasis parameters. Hemostasis parameters 
are shown in Table I. Besides the expected abnor- 
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Fig. 3. Cumulative fluid balance (means and standard error of mean in milliliters) in group I (solid bars) 
and in group II (dotted bars) on arrival in ICU (OR period), on arrival on ward (ICUperiod), and on leaving 
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Fig. 4. Hemoglobin (HI)) in means plus or minus standard error of mean in group I men (solid squares) 
and women (solid circles) and in group II men (open squares) and women (open circles). Samples were taken 
before operation (TO), after administration of heparin before extracorporeal circulation (TI), after 
administration of protamine after extracorporeal circulation (T2), at end of operation (T3), 2 hours after 
operation in ICU (T4), 6 hours after operation in ICU (TS), 24 hours after operation (T6), and on 
postoperative day 5 (TT). 
malities caused by heparinization (causing prolon- 
gation of the aPTT), the values in both groups 
remained within the normal range. There were no 
significant differences between groups. The same 
was true for the PT. Thrombocyte counts showed 
the typical course seen during and after operations 
with CPB. Finally, no significant differences were 
found between the two groups in the amount of 
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Table I. Hemostasis parameters in groups I (FFP) and H (no FFP) 
Thrombocytes 
aPTT (sec) PT (see) (platelets/gl × 10 9) 
Sample Group I Group II Group I Group II Group I Group II 
TO 24 -+ 3 23 + 2 15 ± 1 13 -+ 1 226 + 14 223 -+10 
T1 >300 >300 >40 >40 208 --- 14 207 + 12 
T2 36 -+ 4 34 ± 4 20 -+ 2 17 -+ 1 131 ± 9 133 ± 6 
T3 30-+4 34±44 19±1 18-+1 135±10 139±7 
T4 42 ± 7 36 ± 5 16 + 1 17 + 1 160 ± 10 161 -+ 8 
T5 27 -+ 3 25 ± 3 17 ± 1 16 ± 1 147 ± 8 152-+ 7 
T6 28-+4 26 +3 20±1 17-+1 142±9 141±7 
T7 32 ± 3 32 - 4 15 ± 2 17 -+ 2 200 --+ 11 211 ± 10 
Values given as means plus or minus the standard e ror of the mean. TO, Before operation; 7'1, after administration of heparia before extracorporeal 
circulation; T2, after administration of protamine after extracorporeal circulation; 7"3, at end of operation; T4, 2 hours after operation in ICU; TS,6 hours 
after operation in ICU; T6,24 hours after operation; TT, fifth postoperative day. There were no significant differences among values. 
heparin administered per kilogram of body weight 
and the subsequent amount of protamine used. 
Discussion 
In this study no beneficial effects of the prophy- 
lactic administration of FFP could be demonstrated 
on blood loss, transfusion requirement, or coagula- 
tion parameters in patients who underwent opera- 
tion with CPB. Many investigations have been done 
with respect o the hemostatic problems often en- 
countered after operations with CPB. In vivo and in 
vitro studies have shown a number of derangements 
of the coagulation cascade, platelet counts, and 
platelet function. 1-6 Recently, however, there have 
been indications that thrombocyte function abnor- 
malities are the most important cause of postoper- 
ative bleeding complications in patients undergoing 
CPB. 9 CPB may cause qualitative and quantitative 
thrombocyte abnormalities, which are probably mul- 
tifactorial.5, 7, 16, 17 Apart from a dilutional effect, 
adhesion to synthetic surfaces (mainly in the oxy- 
genator), formation of platelet aggregates, and ac- 
tivation and injury of platelets as a result of blood- 
air interface may play roles] Additionally, platelet 
counts may be decreased because of mechanical 
damage in the roller pump. 7' 16 Hypothermia lso 
contributes to platelet dysfunction after operation. 
Other causes are platelet aggregation induced by 
pulmonary artery catheters, heparin, protamine, 
heparin-protamine complexes, and adenosine 
diphosphate release from hemolyzed red blood 
cells] Because FFP has no proven effect on platelet 
function there is no reason to transfuse FFP for 
correction of these abnormalities. 6 Coagulation ab- 
normalities eem to be transient and clinically less 
important. The dilution of coagulation factors has 
been described by various authorsJ' 2, 5, 6 However, 
as also observed in our study, coagulation parame- 
ters remain well above the levels normally consid- 
ered to be adequate for hemostasis. 1'2'5 Further- 
more, the amount of FFP generally transfused (1 to 
2 units) is inadequate for restoring a severely im- 
paired coagulation system. 6 As a consequence, rou- 
tine transfusion of FFP after operations with CPB is 
not justified. 
Finally, CPB has been shown to influence the 
fibrinolytic system. 3 The presence of fibrin-split 
products during and immediately after extracorpo- 
ral circulation is common. How the fibrinolytic 
system is activated isnot yet completely understood; 
it is probably triggered through various pathways. 3 
Reports on the successful use of antifibrinolytic 
agents, such as (e-aminocaproic acid) and ana- 
logues, do suggest hat plasminogen may play an 
essential role. 3 Furthermore, aprotinin has been 
reported to reduce blood loss during CPB either by 
a direct effect on platelets or through a secondary 
effect, through inhibition of plasmin or the kallikrein 
system.S, 9 
Nevertheless, many clinicians till administer FFP 
as a prophylaxis against postoperative bleeding in 
cardiac operations. As far as we know, up until now 
only one well-designed clinical study has been done 
to investigate the effect of FFP on postoperative 
blood loss and transfusion requirement after oper- 
ations with CPB. 16 In that study by Boldt and 
colleagues, 16the effect in patients undergoing aor- 
tocoronary bypass of 2 units of FFP given after the 
end of extracorporeal circulation (n = 20) was 
compared with findings in a control group (n = 20) 
that did not receive FFP. Various laboratory param- 
eters, including coagulation data, were measured 
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before and after extracorporeal circulation up to the 
first postoperative day. The major results showed 
that routine administration of  FFP has no beneficial 
effect with respect o hemostatis parameters. 16The 
results of the current study, in which the observation 
period has been extended to 5 days after operation, 
are in accordance with those of this previous inves- 
tigation, thus strengthening the opinion that the 
administration of FFP after operation with CPB is 
not justified. 
It should be kept in mind, moreover, that trans- 
fusion of homologous blood products carries the 
risk of  disease transmission, the most serious of  
which is the immunodeficiency virus. 1°13 Classic 
immunologic transfusion reactions, alloimmuniza- 
tion, and possibly immunosuppression are reasons 
to be very careful with the administration of blood 
products.14, 18 The possible risks of  blood compo- 
nent therapy should always be carefully weighed 
against he beneficial effects. 
In conclusion, the current clinical study shows 
that prophylactic administration of FFP in opera- 
tions with CPB does not decrease blood loss or the 
transfusion requirement of packed red blood cells. 
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